25.47

0.59% -0.15

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $25.47, with a volume of 820.75K. It is down -0.59% in the last 24 hours and down -4.54% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Previous Close:

$25.62

Open:

$25.47

24h Volume:

820.75K

Relative Volume:

0.33

Market Cap:

$4.06B

Revenue:

$295.41M

Net Income/Loss:

$-49.64M

P/E Ratio:

-77.79

EPS:

-0.3274

Net Cash Flow:

$-29.54M

1W Performance:

-2.38%

1M Performance:

-4.54%

6M Performance:

+75.29%

1Y Performance:

+48.86%

1-Day Range:

$24.88

$25.91

1-Week Range:

$24.33

$26.85

52-Week Range:

$12.00

$30.74

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1051)

Industry

Diagnostics & Research (44)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

624

Twitter

@adaptivebiotech

Next Earnings Date

2026-11-04

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT vs TMO, DHR, NTRA, A, IQV

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	25.47	4.06B	295.41M	-49.64M	-29.54M	-0.3274
TMO Thermo Fisher Scientific Inc	693.44	256.40B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	231.61	162.82B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	402.40	58.00B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	176.39	49.73B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	270.11	44.46B	16.63B	1.39B	2.12B	8.0674

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight
Sep-30-25	Initiated	Guggenheim	Buy
Jun-18-25	Initiated	Craig Hallum	Buy
Mar-21-25	Upgrade	Goldman	Neutral → Buy
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

Oct 06, 2026

Adaptive Biotechnologies Officer Susan Bobulsky Files to Sell 6,444 Shares Under 10b5-1 Plan - Kalkine Media

Oct 06, 2026

Oct 05, 2026

Adaptive Biotechnologies COO Julie Rubinstein sells $1m in stock - Investing.com

Oct 05, 2026

Form 4 Adaptive Biotechnologies Corp For: 5 October By Investing.com - Investing.com Nigeria

Oct 05, 2026

An officer exercises options and sells Adaptive Biotechnologies (ADPT) shares under a preset plan. - Stock Titan

Oct 05, 2026

A COO exercises $12.14 options and sells 35,643 Adaptive Biotechnologies (ADPT) shares. - Stock Titan

Oct 05, 2026

Oct 01, 2026

Adaptive Biotechnologies Officer Julie Rubinstein Files Form 144 to Sell 379,777 Shares - Kalkine Media

Oct 01, 2026

Options exercised over three months will supply an officer's planned sale at Adaptive Biotechnologies (ADPT). - Stock Titan

Oct 01, 2026

Sep 28, 2026

Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com - Investing.com Canada

Sep 28, 2026

Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com - Investing.com South Africa

Sep 28, 2026

Sep 18, 2026

Adaptive Biotechnologies (ADPT) HR chief sells over 100,000 shares under preset plan - Stock Titan

Sep 18, 2026

Sep 17, 2026

Adaptive biotechnologies chief commercial officer sells $32,265 in shares. - Investing.com

Sep 17, 2026

Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells shares under pre-set trading plan - Stock Titan

Sep 17, 2026

Sep 16, 2026

Adaptive Biotechnologies (ADPT) officer to sell 142K shares - Stock Titan

Sep 16, 2026

Sep 15, 2026

Officer at Adaptive Biotechnologies (NASDAQ: ADPT) plans sale of 1,195 shares - Stock Titan

Sep 15, 2026

Sep 02, 2026

Adaptive Biotechnologies (NASDAQ: ADPT) director reports stock gift, still holds 66,100 shares - Stock Titan

Sep 02, 2026